HPS Pharmacies wish to advise that Pfizer is experiencing a supply interruption for Heparinised Saline as follows:
Heparin sodium 50 IU/5mL
This supply interruption is expected to resolve by late July 2023.
An internationally registered alternative has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. This product is registered for use in the United Kingdom, and all packaging is in English. It is identical to the Australian registered product for active ingredient, strength, and excipients. However, there are some presentation differences, as shown in the table below.
|Australian Product||S19A Product|
|Labelled as||Heparinised saline||Flushing solution|
|Pack size||50 ampoules||10 ampoules|
|Presentation||LDPE ampoules||Glass ampoules|
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pfizer on 1800 675 229 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates